Condensed N-heterocyclic Compounds and Their Use as Crf Receptor Antagonsts

Content Provider	Semantic Scholar
Copyright Year	2017
Abstract	The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 lkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, —C(O)R. nitro, hydroxy, NRR, cyano and or a group Z: R is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alk enyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NRR or cyano; D, G is —C optionally substi tuted; X is carbon or nitrogen: Y is nitrogen or —Coptionally substituted; W is a 4-8 membered ring, which may be saturated or may contain one to three double bonds, and in which:—one carbon atom is replaced by a carbonyl or S(O), and—one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR, S(O), carbonyl, and such ring may be further substituted by 1 to 8 substituents: Z is a 5-6 membered heterocycle, which may be substituted by 1 to 8 Rs groups or a phenyl ring, which may be substituted by 1 to 4 substituents; m is an integer from 0 to 2. to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treat ment of conditions mediated by corticotropin-releasing fac tor (CRF).
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://patentimages.storage.googleapis.com/c1/cd/e3/4da0c11e7e5904/US20070004708A1.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article